Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) EPS (Weighted Average and Diluted) (2023 - 2025)

Goldenwell Biotech filings provide 3 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.0 for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 65.38% to -$0.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$0.0, a 65.38% increase, with the full-year FY2024 number at -$0.0, down 12.05% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.0 in Q3 2025 for Goldenwell Biotech, down from -$0.0 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.0 in Q4 2024 to a low of -$0.0 in Q2 2024.
  • Median EPS (Weighted Average and Diluted) over the past 3 years was -$0.0 (2023), compared with a mean of -$0.0.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): skyrocketed 426.77% in 2024 and later fell 10.69% in 2025.
  • Goldenwell Biotech's EPS (Weighted Average and Diluted) stood at -$0.0 in 2023, then skyrocketed by 426.77% to $0.0 in 2024, then plummeted by 112.06% to -$0.0 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.0 (Q3 2025), -$0.0 (Q2 2025), and -$0.0 (Q1 2025) per Business Quant data.